|
2024
|
Invention
|
Substituted quinazolines as inhibitors of kras g12c.
Compounds having activity as inhibitors of ... |
|
2023
|
Invention
|
Inhibitors of kras g12c.
Compounds having activity as inhibitors of G12C mutant KRAS protein are... |
|
2022
|
Invention
|
Fused n-heterocyclic compounds and methods of use thereof.
Compounds having activity as inhibito... |
|
|
Invention
|
Covalent inhibitors of kras.
Compounds having activity as inhibitors of G12C mutant KRAS protein... |
|
2020
|
Invention
|
Substituted quinazolines as inhibitors of kras g12c. Compounds having activity as inhibitors of G... |
|
|
Invention
|
Covalent inhibitors of kras. Compounds having activity as inhibitors of G12C mutant KRAS protein ... |
|
2019
|
Invention
|
Compounds and methods of use thereof for treatment of cancer.
Compounds having activity as inhib... |
|
|
Invention
|
Compounds and methods of use thereof for treatment of cancer. Compounds having activity as inhibi... |
|
|
Invention
|
2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and rel... |
|
|
Invention
|
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer. 2, E, W, X, ... |
|
|
Invention
|
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer. Compounds ha... |
|
|
Invention
|
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of us... |
|
|
Invention
|
Substituted cinnolines as inhibitors of kras g12c. Compounds having activity as inhibitors of G12... |
|
|
Invention
|
Inhibitors of kras g12c mutant proteins. Compounds having activity as inhibitors of G12C mutant K... |
|
|
Invention
|
Covalent inhibitors of kras g12c. Irreversible inhibitors of G12C mutant K-Ras protein are provid... |
|
|
Invention
|
Substituted quinazoline compounds and methods of use thereof. Compounds having activity as inhibi... |
|
2018
|
Invention
|
Combination therapies for treatment of cancer.
Combination therapies for treatment of cancers as... |
|
|
Invention
|
Quinazoline derivatives as modulators of mutant kras, hras or nras. 2 are as defined herein. Meth... |
|
|
Invention
|
Quinazoline derivatives as modulators of mutant kras, hras or nras. Compounds having activity as ... |
|
|
Invention
|
Benzothiophene and benzothiazole compounds and methods of use thereof. 1 and E are as defined her... |
|
|
Invention
|
Fused hetero-hetero bicyclic compounds and methods of use thereof. Compounds having activity as i... |
|
|
Invention
|
Benzothiophene and benzothiazole compounds and methods of use thereof. Compounds having activity ... |
|
|
Invention
|
Fused n-heterocyclic compounds and methods of use thereof. Compounds having activity as inhibitor... |
|
|
Invention
|
Substituted quinazoline and quinazolinone compounds and methods of use thereof. 1 and E are as de... |
|
|
Invention
|
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and s... |
|
|
Invention
|
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof. Compounds having activit... |
|
|
Invention
|
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and simi... |
|
|
Invention
|
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and si... |
|
2017
|
Invention
|
Method for screening inhibitors of ras.
Provided herein are compositions, reactions mixtures, mu... |
|
|
Invention
|
Substituted quinazoline compounds and methods of use. The present disclosure provides inhibitors ... |
|
2016
|
Invention
|
Inhibitors of kras g12c mutant proteins. 2 and E are as defined herein. Methods associated with p... |
|
|
Invention
|
Inhibitors of kras g12c mutant proteins. 4, and E are as defined herein. Methods associated with ... |
|
|
Invention
|
Inhibitors of kras g12c mutant proteins. 4, n and E are as defined herein. Methods associated wit... |
